Pycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55

Journal of Neurosurgical Sciences

Volumn 58, Issue 4, 2014, Pages 239-248

  Belcaro, G ^a   Luzzi, R ^a   Dugall, M ^a   Ippolito, E ^a   Saggino, A ^b  

^a Pescara Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cognitive therapy; Dietary supplements; Oxidative stress; Pycnogenols

Indexed keywords

FREE RADICAL; PYCNOGENOL; ANTIOXIDANT; FLAVONOID; PYCNOGENOLS;

ADULT; ALCOHOL CONSUMPTION; ALERTNESS; ANXIETY; ARTICLE; ATTENTION; COGNITION; DIET; DRUG TOLERABILITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXERCISE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIFESTYLE; MALE; MENTAL PERFORMANCE; MOOD; NORMAL HUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; RECALL; RECOGNITION; SKILL; WORKING MEMORY; BLOOD; CLINICAL TRIAL; DIETARY SUPPLEMENT; DRUG EFFECTS; MIDDLE AGED;

ADULT; ANTIOXIDANTS; ATTENTION; COGNITION; DIETARY SUPPLEMENTS; EXECUTIVE FUNCTION; FEMALE; FLAVONOIDS; FREE RADICALS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84926308326     PISSN: 03905616     EISSN: 18271855     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Chowdhury R, Guitart-Masip M, Bunzeck N, Dolan RJ, Düzel E. Dopamine modulates episodic memory persistence in old age. J Neurosci 2012;32:193-204.
2. Tsang BK, Crump N, Hughes AJ. A patient with steroid responsive encephalopathy associated with autoimmune thyroiditis. J Clin Neurosci 2012;19:59-61.
3. Csábi E, Várszegi M, Sefcsik T, Németh D. Effect of two month positive airway pressure therapy on the structure of sleep, cognitive function and anxiety]. Ideggyogy Sz 2012;65:181-94.
4. Koh MT. Pharmacological treatment strategies targeting cognitive impairment associated with aging]. Nihon Yakurigaku Zasshi 2012;139:157-9.
5. Depp CA, Savla GN, de Dios LA, Mausbach BT, Palmer BW. Affective symptoms and intra-individual variability in the shortterm course of cognitive functioning in bipolar disorder. Psychol Med 2012;42:9-16.
6. Gan EH, Pearce SH. Clinical review: The thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 2012;97:38-49.
7. Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. Am Fam Physician 2012;86:244-51
8. Parrat D, Meyer P. Endocrinology in 2012: what's new?]. Rev Med Suisse 2013;9:36-9
9. van Mil NH, Tiemeier H, Bongers-Schokking JJ, Ghassabian A, Hofman A et al. Low urinary iodine excretion during early pregnancy is associated with alterations in executive functioning in children. J Nutr 2012;142:2167-74.
10. Resta F, Triggiani V, Barile G, Benigno M, Suppressa P, Giagulli VA et al. Subclinical hypothyroidism and cognitive dysfunction in the elderly. Endocr Metab Immune Disord Drug Targets 2012;12:260-7.
11. Maggio M, Dall'Aglio E, Lauretani F, Cattabiani C, Ceresini G, Caffarra P et al. The hormonal pathway to cognitive impairment in older men. J Nutr Health Aging 2012;16:40-54.
12. Etgen T, Sander D, Bickel H, Forstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int 2011;108:743-50.
13. Cornelli U, Belcaro G, Ledda A, Feragalli B. Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. Panminerva Med 2011;53(3 Suppl 1):99-103.
14. Cornelli U, Belcaro G, Ledda A, Feragalli B. Oxidative stress following administration of levothyroxine in subjects suffering from primary hypothyroidism. Panminerva Med 2011;53(3 Suppl 1):95-8.
15. Lucke JC, Bell SK, Partridge BJ, Hall WD. Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals. EMBO Rep 2011;12:197-201.
16. Belcaro G, Cesarone MR, Steigerwalt RJ, Di Renzo A, Grossi MG, Ricci A et al. Jet-lag: prevention with Pycnogenol. Preliminary report: evaluation in healthy individuals and in hypertensive patients. Minerva Cardioangiol 2008;56(5 Suppl):3-9.
17. Elsabagh S, Hartley DE, Ali O, Williamson EM, File SE. Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers. Psychopharmacology (Berl). 2005;179:437-46.
18. Luzzi R, Belcaro G, Zulli C, Cesarone MR, Cornelli U, Dugall M, Hosoi M et al. Pycnogenol supplementation improves cognitive function, attention and mental performance in students. Panminerva Med 2011;53(3 Suppl 1):75-82
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatric Scand 1983;67:361-70.
20. Nelson HE, Willison JR. Restandardisation of the NART against the WAIS-R. NFER-Nelson, Windsor, UK; 1991.
21. Spreen O, Strauss E. A compendium of neuropsychological tests: administration norms and commentary. Oxford University Press, New York; 1991.
22. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalohippocampectomy in man. Neuropsychologia 1995;33:1-24.
23. Weingartner HJ, Joyce EM, Sirocco KY, Adams CM, Eckardt MJ, George T et al. Specific memory and sedative effects of the benzodiazepine triazolam. J Psychopharm 1993;7:305-15.
24. Snodgrass JG, Vanderwart M. A standardized set of 260 pictures: norms for name agreement, image agreement, familiarity, and visual complexity. J Exp Psychol Hum Learn Mem 1980;6:174-215.
25. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990;28:1021-34.
26. Owen AM, Roberts AC, Polkey CE, Robbins TW. Extradimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalohippocampectomy in man. Neuropsychologia 1991;29:993-1006.
27. Rogers RD, Andrews TC, Grasby PM, Brooks DJ, Robbins TW. Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cogn Neurosci 2000;12:142-62.
28. Owen AM, Doyon J, Petrides M, Evans AC. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 1996;8:353-64.
29. Bond AJ, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-8.
30. Belcaro G, Cesarone MR, Errichi BM, Ledda A, Stuard S, Dugall. M. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005;56:699-705.
31. ® accelerates wound healing and reduces scar formation. Phytother. Res 2004;18; 579-81.
32. Calliste CA, Trouillas P, Allais DP, Duroux JL. Castaneas ativa Mill. leaves as new sources of natural antioxidant: an electronic spin resonance study. J Agric Food Chem 2005;53:282-8.
33. ® in humans involves COX-2 and 5-LOX m RNA expression in leukocytes. Int. Immunopharmacol 2005;9; 1145-9.
34. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ippolito E, Scoccianti M et al. Prevention of edema in long flights with Pycnogenol. Clin Appl Thromb Hemost 2005;11:289-4.
35. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol: a prospective, controlled study. Angiology 2006;57; 569-76.
36. Devaraj S, Vega López S, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-4.
37. ®). Free Radical Biol Med 2004;36:811-22.
38. ®) after oral administration to healthy volunteers. BMCClin. Pharmacol 2006;6:1-12.
39. ®). J Inflamm 2006;3; 1-15.
40. ® for treatment in chronic venous insufficiency. Phytother Res 2002;16:1-5.
41. ® in chronicvenous insufficiency. Phytomedicine 2000;7; 383-8.
42. ®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res 2008;22:518-23.
43. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G et al. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep 2008;13:271-6.
44. Hu S. Dugall M. Mood and Pycnogenol Data on file; 2012
45. Putter M, Grotemeyer KHM, Wurthwein G, Araghi-Niknam RR, Watson RR, Rohdewald P. Inhibition of smoking-induced platelet aggregation by aspirin and Pycnogenol. Thromb Res 1999;95; 155-6l.
46. ®), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40; 158-68.
47. Schmidtke I, Schoop W. Das hydrostatische Ödemunds eine medikamentöse Beeinflussung. SwissMed 1984;6:67-9.
48. USP, 2005-Maritime pine extract. In: United States Pharmacopoeia, US Pedition 28. United States Pharmacopeial Convention, Inc.; Rockville 2005; p. 2115-6.
49. Vinciguerra G, Belcaro G, Rohdewald P, Stuard S, Ricci A. Cramps and muscular pain: prevention with Pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006;57:331-9.
50. Williamson G, Manach C. Bioavailability, bioefficacy of polyphenols in humans. II. Review of 93 studies. Am J Clin Nutr 2005;81:243-55.
51. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L et al. A simple test to monitor oxidative stress. Int Angiol 1999;18:127-30
52. Maxwell C. Clinical research for all. Oxford: Oxford University Press; 1989.
53. Campise M, Bamonti F, Novembrino C, Ippolito S, Tarantino A, Comelli U et al. Oxidative stress in kidney transplant patients. Transplantation 2003;76:1474-8.
54. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M, Cacchio M et al. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int Angiol 2001;20:136-40.
55. Comelli U. Antioxidant use in nutraceuticals. Clin Dermatol 2009 Mar-Apr; 27:175-94
56. Marshal J. l Underperformance Syndrome - how youth rugby coaches are using psychology to raise their players' game http://www.pponline.co.uk/encyc/underperformance-syndrome.html
57. ® on fitness in normal subjects with the Army Physical Fitness Test and in performances of athletes in the 100-minute triathlonj Sports Med Phys Fitness 2013;53:1-2
58. Cornelli U. Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis 2010;7:193-202.
59. Mockler D, Riordan J, Sharma T A comparison of the NART (restandardized) and the NART-R (revised). Br J Clin Psychol 1996;35(Pt 4):567-72.